Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warning Letter To Xanodyne Cites Risk Info Omissions In Brochure

Executive Summary

An FDA warning letter to Xanodyne Pharmacal cites a lack of product risk information in a corporate brochure

You may also be interested in...

Shire's $187.5 mil. purchase of Richwood will bring U.S. marketing presence.

SHIRE TO GAIN U.S. MARKETING ARM THROUGH $185.7 MIL. RICHWOOD PURCHASE if the deal is approved by Shire shareholders Aug. 20, Hampshire, England-based Shire Pharmaceuticals said. The company announced Aug. 4 the proposed acquisition of Florence, Ky.-based Richwood Pharmaceuticals for $145.8 mil. in stock (31% of Shire's equity), $15 mil. in cash, and 7.2 mil. options valued at $24.9 mil. Richwood will be Shire's second acquisition this year: the company acquired the Gaithersburg, Md.-based drug delivery company Pharmavene in February for $90.5 mil.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts